Oral · GLP-1 agonist
Lotiglipron
11 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
11
Active
0
Recruiting
0
Completed
7
Sites
91
Countries
10
Endpoints
392
Composite endpoints
18
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
10
Phase 2
1
Trials by status
Completed
7
Terminated
4
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
331
Weight & body composition
26
Glycemic / diabetes
22
Patient-reported / QoL
8
Renal / kidney
5
Most-measured metrics
Top 20 metrics across this asset's endpoints
AUC₀–∞Safety/PK
35
CmaxSafety/PK
28
TmaxSafety/PK
21
Treatment-emergent AEs (any)Safety/PK
18
Half-lifeSafety/PK
18
Body weight, % changeWeight
13
HOMA-IR (insulin sensitivity)Glycemic
8
Waist circumference, changeWeight
4
HbA1c, % changeGlycemic
4
Fasting glucose, changeGlycemic
4
HbA1c, changeGlycemic
4
Serious AEs (any)Safety/PK
4
Discontinuation due to AESafety/PK
4
Documented hypoglycemiaSafety/PK
4
HbA1c <7.0% achievementGlycemic
2
Body weight, absolute change (kg)Weight
1
≥15% weight-loss respondersWeight
1
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
11 of 11